Literature DB >> 10678609

Heparin-induced hyperkalemia confirmed by drug rechallenge.

M P Orlando1, M E Dillon, M W O'Dell.   

Abstract

Subcutaneous heparin is commonly used as a prophylaxis against deep venous thrombosis in a wide variety of hospitalized patients. As with most medications, heparin has a significant side effect profile; heparin-induced hyperkalemia is an unusual but well described side effect. To increase awareness of heparin-induced hyperkalemia and of those patients at greatest risk, we present two cases of documented hyperkalemia induced by heparin and reconfirmed by drug rechallenge.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10678609     DOI: 10.1097/00002060-200001000-00019

Source DB:  PubMed          Journal:  Am J Phys Med Rehabil        ISSN: 0894-9115            Impact factor:   2.159


  4 in total

Review 1.  Hyperkalemia revisited.

Authors:  Walter A Parham; Ali A Mehdirad; Kurt M Biermann; Carey S Fredman
Journal:  Tex Heart Inst J       Date:  2006

2.  Variations of serum potassium level and risk of hyperkalemia in inpatients receiving low-molecular-weight heparin.

Authors:  Giuseppe Gheno; Leonardo Cinetto; Carmelo Savarino; Sandro Vellar; Maurizio Carraro; Massimo Randon
Journal:  Eur J Clin Pharmacol       Date:  2003-07-08       Impact factor: 2.953

3.  Effect of heparin and low-molecular weight heparin on serum potassium and sodium levels.

Authors:  Girish M Bengalorkar; N Sarala; P N Venkatrathnamma; T N Kumar
Journal:  J Pharmacol Pharmacother       Date:  2011-10

4.  Effects of 8,000 IU aXa long-term prophylaxis with certoparin on the incidence of hyperkalemia in patients with coronary heart disease--a post-hoc analysis of the PARAT trial.

Authors:  Nima Melzer; Peter Bramlage; Hans-Christoph Michaelis
Journal:  BMC Res Notes       Date:  2014-12-06
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.